Currently, patients with trastuzumab resistant breast cancers are treated with chemotherapy and lapatinib, a dual pharmacological EGFR and ErbB2 inhibitor that targets the intrinsic kinase domains of these two receptors. This evidence concerns the gene ERBB2 and breast carcinoma.